Absolute oral bioavailability of almorexant, a dual orexin receptor antagonist, in healthy human subjects

Pharmacology

Volumn 89, Issue 1-2, 2012, Pages 53-57

  Hoch, Matthias ^a   Hoever, Petra ^a   Zisowsky, Jochen ^a   Priestley, Anthony ^b   Fleet, David ^c   Dingemanse, Jasper ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

^b LCG Bioscience   (United Kingdom)

^c Data Magik Limited   (United Kingdom)

Author keywords

Almorexant; Bioavailability; Orexin; Pharmacokinetics

Indexed keywords

ALMOREXANT; OREXIN; OREXIN 1 RECEPTOR; OREXIN 2 RECEPTOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FIRST PASS EFFECT; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ACETAMIDES; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; BIOLOGICAL AVAILABILITY; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; INFUSIONS, INTRAVENOUS; ISOQUINOLINES; MALE; MIDDLE AGED; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NEUROPEPTIDE;

EID: 84856455874     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000335367     Document Type: Article

References (9)

1. Sakurai T: The neural circuit of orexin (hypocretin): Maintaining sleep and wakefulness. Nat Rev Neurosci 2007; 8: 171-181.
2. Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, Williams SC, Richardson JA, Kozlowski GP, Wilson S, Arch JR, Buckingham RE, Haynes AC, Carr SA, Annan RS, McNulty DE, Liu WS, Terrett JA, Elshourbagy NA, Bergsma DJ, Yanagisawa M: Orexins and orexin receptors: A family of hypothalamic neuropeptides and G proteincoupled receptors that regulate feeding behavior. Cell 1998; 92: 573-585.
3. Tsujino N, Sakurai T: Orexin/hypocretin: A neuropeptide at the interface of sleep, energy homeostasis, and reward system. Pharmacol Rev 2009; 61: 162-176.
4. Nishino S: The hypocretin/orexin receptor: Therapeutic prospective in sleep disorders. Expert Opin Investig Drugs 2007; 16: 1785-1797.
5. Brisbare-Roch C, Dingemanse J, Koberstein R, Hoever P, Aissaoui H, Flores S, Mueller C, Nayler O, Van Gerven J, de Haas SL, Hess P, Qiu C, Buchmann S, Scherz M, Weller T, Fischli W, Clozel M, Jenck F: Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat Med 2007; 13: 150-155.
6. Hoever P, de Haas S, Winkler J, Schoemaker RC, Chiossi E, Van Gerven J, Dingemanse J: Orexin receptor antagonism, a new sleeppromoting paradigm: An ascending singledose study with almorexant. Clin Pharmacol Ther 2010; 87: 593-600.
7. Hoch M, Hoever P, Haschke M, Krahenbuhl S, Dingemanse J: Food effect and biocomparison of two formulations of the dual orexin receptor antagonist almorexant in healthy male subjects. J Clin Pharmacol 2011; 51: 1116-1121.
8. Hoch M, Hoever P, Alessi F, Marjason J, Dingemanse J: Pharmacokinetics and tolerability of almorexant in Japanese and Caucasian healthy male subjects. Pharmacology 2011; 88: 121-126.
9. Mahmood I: Interspecies Pharmacokinetic Scaling: Principles and Application of Allometric Scaling. Maryland, Pine House Publishers, 2005.